Researchers from Laval University in Quebec in collaboration with researchers from GlaxoSmithKline vaccines, are experimenting with a molecule that within a year could lead to a ” vaccine for Alzheimer’s .” This is a molecule similar to TFP5 . Both of these molecules have been shown to cancel plaques and accumulations of amyloid when injected into mice with a human Alzheimer disease equivalent .

Research on TFP5 dates back to January 2013 and was published in the FASEB Journal by researchers at the National Institutes of Health , and showed that this molecule is able to reverse the symptoms and restore memory , without apparent toxic side effects.

TFP5 derives from the regulator of a brain enzyme called Cdk5 whose over-activation is considered the key factor of the alterations of Alzheimer’s disease.

The molecule similar now experienced by Glaxo and the University of Quebec could lead to the development of a vaccine in a short time , but require new studies directly on humans.